Cytokinetics to Announce Results from BENEFIT-ALS at 66th Annual Meeting of the American Academy of Neurology

Cytokinetics, Incorporated announced today that results from BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS) will be presented during a Platform Session scheduled at the 66th Annual Meeting of the American Academy of Neurology (AAN) to be held April 26 – May 3, 2014 at the Pennsylvania Convention Center in Philadelphia, PA.

The RASCALS Board of Directors Salutes Its Remarkable RASCALS Volunteers

Robert Stehlin and the entire Board of Directors would like to once again recognize the tremendous efforts of our RASCALS Volunteer Army.

Mayo Clinic Researchers Place ALS Hope in Stem Cells

The trial is a safety study to determine if it’s safe to give ALS patients injections of stem cells grown from samples of their own fat tissue.

Final Results of ALS Phase I Stem Cell Trial Published in Annals of Neurology

The results showed that NSI-566 human spinal cord stem cells can be safely transplanted in both the lumbar and cervical spinal cord segments, did not accelerate disease progression, and warrant further study on dosing and therapeutic efficacy in ALS patients.

Why is Lou Gehrig’s Disease Closely Related to Veterans?

Why are military veterans, particularly those who served in the First Gulf War, twice as likely to get ALS when compared to the rest of the population? Since 2008, the Veterans Administration has recognized that there’s a clear link between ALS and military service, and the agency considers it to be a service-connected disability.

BrainStorm and Mass General Sign Definitive Agreement for ALS Clinical Trial

BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Massachusetts General Hospital (MGH) in Boston, MA to conduct a Phase II clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS).

ALS Researchers Uncover New Insights into Motor Neuron Death

According to Brian Kaspar, MD, a principal investigator in the Center for Gene Therapy at Nationwide Children’s and senior author of the new study, inhibiting NF-kB in microglia decreased ALS progression by 47 percent. “

ALS Toxicity Reduced in Animal Models

In a new study published in Nature Genetics, University of Pennsylvania researchers and colleagues have made inroads into the mechanism by which ALS acts. Working with a powerful fruit fly model of the disease, they found a way of reducing disease toxicity that slows the dysfunction of neurons and showing that a parallel mechanism can reduce toxicity in mammalian cells. Their discoveries offer the possibility of a new strategy for treating ALS.

Biomarkers Help Predict Progress of ALS

While the size of this study is small, the ability of the specific biomarkers used to predict ALS prognosis suggests that the approach holds promise.

New Gene Variant Discovered for ALS

Research led by King’s College London has identified a new genetic variant, located on chromosome 17, associated with sporadic amyotrophic lateral sclerosis (ALS) – the most common form of motor neurone disease (MND).